Meeting
2013 ASCO Annual Meeting
Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma.
Authors
Maria Vasilakopoulou
Yale University, New Haven, CT
Maria Vasilakopoulou , Vamsidhar Velcheti , Theodoros Rampias , Clarence Sasaki , David Rimm , George Fountzilas , Amanda Psyrri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6012)
DOI
10.1200/jco.2013.31.15_suppl.6012
Abstract #
6012
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).
First Author: Himisha Beltran
Poster
2023 ASCO Annual Meeting
Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.
First Author: Ghanashyam Biswas
Poster
2022 ASCO Annual Meeting
Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.
First Author: Chang Gon Kim
Poster
2021 ASCO Annual Meeting
Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
First Author: Alain Patrick Algazi